Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering

This publication has 30 references indexed in Scilit:

• Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy
  Circulation, 2012
• On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy
  JACC, 2012
• Three Reasons to Abandon Low-Density Lipoprotein Targets
  Circulation: Cardiovascular Quality and Outcomes, 2012
• Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference
  Canadian Journal of Cardiology, 2011
• Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
  Journal of Clinical Lipidology, 2011
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
  The Lancet, 2010
• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
  The Lancet, 2010
• Major Lipids, Apolipoproteins, and Risk of Vascular Disease
  JAMA, 2009
• Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
  New England Journal of Medicine, 2008
• Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice
  Journal of Clinical Lipidology, 2008